Penicillin-Based Amoxicillin: Treatment | Bacterial Infections

USAntibiotics Resumes Amoxicillin Production at Bristol, TN Facility

USAntibiotics, the sole authorized American producer of penicillin-based antibiotics like Amoxicillin and Amoxil Clavulanate (commonly known as Amoxil® and Augmentin®), has resumed operations at its Bristol, Tennessee manufacturing facility. This marks the return of American ownership after the plant fell into bankruptcy last year.

Production Capacity and National Supply Chain Impact

Once fully operational, the 360,000-square-foot facility will have the capacity to produce 300 million capsules and 2 billion tablets annually, with the ability to store a five-year supply of Amoxicillin for the United States. About a third of all antibiotics prescribed in the U.S. are Amoxicillin, and USAntibiotics will be the only American company capable of manufacturing this essential medication. At full capacity, the facility can meet 100% of U.S. demand, ensuring a secure supply of Amoxicillin.

Securing America's Antibiotic Supply Chain

"As the first doses of USAntibiotics' life-saving drugs roll off the production line, America declares its independence from foreign antibiotics," said Rick Jackson, founder, CEO, and chairman of Jackson Healthcare. "Our mission is to eliminate reliance on foreign Amoxicillin sources and establish a long-term, stable supply chain. Today, the United States is back in the business of producing critical medications."

Shane Jackson, president of Jackson Healthcare, added, "Before acquiring USAntibiotics, we heard many stories of employees who continued to work without pay to keep the plant running during bankruptcy. Their dedication to producing vital medications, even in difficult times, shows their commitment to solving long-term supply chain challenges."

Government Support and National Security Concerns

Tennessee Governor Bill Lee and Congresswoman Diana Harshbarger are among the officials attending the ribbon-cutting ceremony at the USAntibiotics facility. In recent years, the U.S. pharmaceutical industry has faced growing concerns about dependence on foreign antibiotic sources, primarily from China.

In 2008, all U.S.-administered doses of Amoxil and Augmentin were produced domestically. Over time, American drug production capacity dwindled, leading to a reliance on foreign manufacturers. This situation has raised significant national security and supply chain concerns.

President Joe Biden recently ordered a review of critical U.S. supply chains, including pharmaceuticals. The consolidation of foreign drug supply chains has left essential medications vulnerable to disruptions from mismanagement, natural disasters, pandemics, and economic weaponization. USAntibiotics' return to production is one of the first private-sector initiatives aimed at strengthening America’s pharmaceutical manufacturing capacity.